A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer

Brief Overview of

Inclusion Criteria:

- Patients must have pathologically confirmed ovarian cancer, which is advanced or
recurrent carcinoma, who have failed at least two, but no more than three prior
therapies for metastatic disease

- Patients must have > 20% Lewis-y antigen expression documented by
immunohistochemistry

- LVEF > 50% by echo or MUGA

- Must be platinum resistant as defined by:

- Progression while on initial platinum therapy or

- Progression while on retreatment with initial platinum regimen or

- Relapse < 6 months after initial therapy

Brief Overview of Exclusion Criteria:

- Patients who have had prior therapy with Gemzar®

- Cumulative anthracycline exposure > 300 mg/m2

- More than three prior chemotherapy regimens for ovarian cancer (Retreatment with
Taxane/Platinum after initial combination is considered only one regimen)